Immunogenicity Outcomes for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products Phase II Trial
Effectiveness of immunogenicity was assessed by measuring the geometric mean titer of neutralizing antibody to live SARS-CoV-2, and the geometric mean titer of specific IgG antibody to whole SARS-CoV-2 antigen.
- Neutralizing Antibody Outcomes
- Specific IgG Antibody Outcomes
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Safety Outcomes for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products Phase II Trial
Immunogenicity Outcomes for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products Phase II Trial
Figure 3. Antibody Responses 14 Days After the Second Dose in the Phase 2 Trial
Wuhan Institute of Biological Products Vaccine Specifics (phases 1+2)